Objective: To investigate autonomic modulation of the sinus node, by analyzing heart rate variability (HRV) among young and middle-aged individuals, and to assess the effect of an resistance strength training program on this modulation among middleaged individuals. Method: Thirty-two healthy nonsmoking men with sedentary lifestyles, of whom 10 were young (22.2 ± 1.5 years) and 22 were middle-aged (49.3 ± 5.3 years), underwent electrocardiogram signal acquisition for time-domain HRV analysis. The middle-aged individuals were divided into two groups: experimental (n= 12) and control (n= 10). The individuals in the experimental group were enrolled in a strength training program lasting three months. The data analysis was carried out using the Wilcoxon and Mann-Whitney tests (p< 0.05). Results: The middle-aged group presented significant reductions (in relation to the young group) for all the variables used in investigating HRV (SDNN= 33.4 vs. 49.7 ms; RMSSD= 29.9 vs. 49.5 ms; pNN50= 6.5 vs. 27%). The training caused a significant increase in muscle strength and resistance for all muscular groups and non-significant increases in the variables SDNN (33.4 vs. 37.6 ms), RMSSD (30.2 vs. 31.3 ms) and pNN50 (7.5 vs. 11.4%). Conclusions: The findings from this study confirm that increased age causes alteration to the autonomic modulation of the sinus node, as demonstrated by reduced HRV in middle-aged individuals, which was not significantly modified by the type of physical training studied.

In order to evaluate the main adverse effects of drug protocols using bortezomib and/or thalidomide for the treatment of multiple myeloma, we conducted a prospective study. Data were collected through interviews, clinical observation, and from hospital records. A total of 59 patients were included. There was a predominance of females, 36 (61%) vs 23 (39%) males, and of whites, 49 (83.1%) vs 10 (16.9%) blacks. Age ranged from 40 to 94 years, with a median of 65 years (SD=11.6). Regarding staging at diagnosis, 27 (45.7%) patients were in stage III-A, with 12 (20.3%) patients having serum creatinine ≥2 mg/dL. The main adverse effects in the bortezomib treatment group (n=40) were: neutropenia (42.5%), diarrhea (47.5%), and peripheral neuropathy in 60% of cases, with no difference between the iv (n=26) and sc (n=14) administration routes (P=0.343). In the group treated with thalidomide (n=19), 31.6% had neutropenia, 47.4% constipation, and 68.4% peripheral neuropathy. Neutropenia was associated with the use of alkylating agents (P=0.038). Of the 3 patients who received bortezomib in combination with thalidomide, only 1 presented peripheral neuropathy (33.3%). Peripheral neuropathy was the main adverse effect of the protocols that used bortezomib or thalidomide, with a higher risk of neutropenia in those using alkylating agents. Improving the identification of adverse effects is critical in multiple myeloma patient care, as the patient shows improvements during treatment, and requires a rational and safe use of medicines.